In collaboration with our academic partner TRICALS, Ferrer is conducting a Phase 3 trial to evaluate the safety and potential efficacy of the investigational drug FNP122 for people with ALS.

FNP122

Oxidative stress is thought to contribute to nerve cell death in ALS. FNP122 is an oral formulation of edaravone, a compound that can help prevent oxidative stress. Therefore, by decreasing oxidative stress, edaravone could potentially slow ALS progression.

All information on the study design, inclusion criteria and participating TRICALS centers can be found here at the TRICALS website.